Related references
Note: Only part of the references are listed.
Article
Microbiology
Chun-Yang Lin et al.
Summary: This study found that prior immunity to common cold coronaviruses does not affect protection against SARS-CoV-2 infection. Instead, higher levels of pre-existing betacoronavirus antibodies are associated with more severe disease following SARS-CoV-2 infection. Additionally, immunization with common cold coronavirus spike proteins hinders the generation of SARS-CoV-2 neutralizing antibodies.
CELL HOST & MICROBE
(2022)
Article
Immunology
Li Tang et al.
Summary: Our study investigates the variability in protective antibody levels against different SARS-CoV-2 variants following infection or vaccination. We found that individuals with increased disease severity, poor metabolic health, and a particular ancestry were more likely to generate cross-reactive antibodies. Vaccination increased cross-reactive antibody levels in all populations, with younger individuals with a healthy weight showing the highest responses. These findings are crucial in informing clinicians about populations who may require additional vaccination.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Cell Biology
Peter J. Halfmann et al.
Summary: The emergence of the SARS-CoV-2 Delta variant has led to concerns about reduced sensitivity to neutralizing antibodies and vaccine breakthrough infections. The study shows a decrease in neutralizing antibody titers against the Delta variant in individuals vaccinated with Pfizer and Moderna vaccines. However, hamsters previously infected with an early isolate of SARS-CoV-2 are still protected against infection with the Delta variant.
Article
Multidisciplinary Sciences
Marciela M. DeGrace et al.
Summary: The SAVE program is a real-time risk assessment initiative established by the National Institute of Allergy and Infectious Diseases to address the public health threat posed by the emergence of SARS-CoV-2 variants. Its goal is to evaluate the potential impact of these variants on transmission, virulence, and immunity induced through infection or vaccination.
Article
Immunology
Kelvin Kai-Wang To et al.
Summary: The study confirmed reinfection in an apparently immunocompetent patient 142 days after the first symptomatic episode, rather than persistent viral shedding. This suggests that SARS-CoV-2 may continue to circulate among humans, even with natural herd immunity, highlighting the need for further research on protective immunological correlates for vaccine design.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Richard L. Tillett et al.
Summary: A man was infected with SARS-CoV-2 twice with genetically different virus variants, the second infection being more severe. The study suggests that previous exposure to SARS-CoV-2 may not guarantee immunity, and all individuals should take precautions to avoid infection. This has implications for vaccine development and application.
LANCET INFECTIOUS DISEASES
(2021)
Letter
Oncology
Adolfo Aleman et al.
Article
Multidisciplinary Sciences
Katherine McMahan et al.
Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.
Article
Medicine, General & Internal
S. F. Lumley et al.
Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jennifer M. Dan et al.
Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.
Article
Medicine, General & Internal
Stefan Pilz et al.
Summary: According to the study in Austria, the rate of SARS-CoV-2 re-infections is relatively low. Protection against SARS-CoV-2 after natural infection is comparable to the highest estimates of vaccine efficacies.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Multidisciplinary Sciences
Juan Manuel Carreño et al.
Letter
Medicine, General & Internal
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Article
Virology
Nikhil S. Sahajpal et al.
Summary: Two public health challenges have emerged in the current COVID-19 pandemic, deficits in SARS-CoV-2 variant monitoring and neglect of other co-circulating respiratory viruses. By evaluating 533 samples using high-throughput sequencing, the study demonstrated the utility of this technology in identifying novel variants to prevent and mitigate viral threats, as well as providing insights into viral transmission patterns.
Article
Medicine, General & Internal
Raymond A. Harvey et al.
Summary: Understanding the impact of serum antibodies to SARS-CoV-2 on infection susceptibility is crucial for identifying at-risk populations and vaccine deployment. Results of the study suggest that individuals with positive antibody test results initially had a higher likelihood of positive NAAT results, but this likelihood decreased significantly over time, indicating that seropositivity may be associated with protection from infection, though the duration of this protection remains uncertain and may decrease over time.
JAMA INTERNAL MEDICINE
(2021)
Article
Immunology
Megan M. Sheehan et al.
Summary: The study found that prior infection in patients with COVID-19 provided a high level of protection against reinfection and symptomatic disease, with this protection increasing over time. This suggests that viral shedding or ongoing immune response may persist beyond 90 days, and may not necessarily represent true reinfection.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
David Forgacs et al.
Summary: In this study, a serological assay was used to measure antibody responses post-vaccination and compared to immune responses from natural infection. The results showed that vaccination induced a more robust immune reaction and that levels of neutralizing and anti-RBD antibody binding were significantly higher in pre-immune participants compared to immunologically naive participants.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Juan Manuel Carreno et al.
Summary: The study found that currently circulating viral variants, including Iota and Delta, show only minimal decreases in neutralization, while the Lambda sub-variant exhibits a significant reduction in neutralization, followed by Beta and Alpha (E484K). Overall, mRNA SARS-CoV-2 vaccines may still be effective against these viral variants, and receptor binding domain and spike binding antibody tests may retain specificity in the face of evolving SARS-CoV-2 diversity.
Article
Medicine, General & Internal
Juanjie Tang et al.
Summary: This study highlights the differences in antibody affinity maturation between individuals with prior COVID-19 infection and naive individuals post mRNA vaccination. Higher neutralizing antibodies were observed in convalescent individuals compared to naive individuals, along with differences in antibody binding and affinity. Additionally, males showed significantly higher antibody affinity against SARS-CoV-2 prefusion spike compared to females among the naive participants. Further research is needed to determine the role of antibody affinity in protection against SARS-CoV-2 and its variants.
Article
Immunology
Joshua G. Petrie et al.
Summary: Reinfection with seasonal HCoVs is frequent, and binding anti-spike protein antibodies do not correlate with protection from seasonal HCoV infection, with little cross-response to SARS-CoV-2 proteins.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Microbiology
Nicholas Wohlgemuth et al.
Summary: This study evaluated the correlation of six serological assays with authentic virus neutralization for SARS-CoV-2. The results showed that luciferase- and SEAP-expressing pseudotyped virus neutralizations were the most accurate in predicting authentic virus neutralization, followed by GFP-expressing pseudotyped virus neutralization, and then ELISAs. This research outlines the advantages and disadvantages of different assays, providing insights into the optimal surrogate assay for authentic virus neutralization and enhancing the accuracy of assessing protective immunity against SARS-CoV-2 post infection and vaccination.
MICROBIOLOGY SPECTRUM
(2021)
Article
Pathology
Nikhil S. Sahajpal et al.
Summary: The clinical performance of saliva compared with nasopharyngeal swabs in detecting SARS-CoV-2 varies depending on the testing protocols. The SalivaAll protocol demonstrates higher sensitivity for saliva samples, indicating the potential for using pooled saliva for SARS-CoV-2 testing.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2021)
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Multidisciplinary Sciences
Nuno R. Faria et al.
Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.
Article
Microbiology
Rachel T. Eguia et al.
Summary: This study investigates the evolution of human coronavirus 229E and finds that as the virus evolves, mutations in the spike protein can escape neutralization by antibodies in old human sera. The results suggest that viral evolution may impact immunity, highlighting the need for periodic updates to coronavirus vaccines.
Article
Medicine, General & Internal
Nikhil S. Sahajpal et al.
Summary: Researchers developed a universal saliva processing protocol (SalivaSTAT) for extraction-free RT-PCR testing, which demonstrated comparable performance to the traditional FDA-EUA method. The protocol showed good positive and negative percent agreements in clinical sample evaluation, with an LoD of 60-180 copies/mL, and further efficiency improvement was achieved using a five-sample pooling strategy.
Article
Medicine, General & Internal
Parakkal Deepak et al.
Summary: Patients with CID show immune response to mRNA-based SARS-CoV-2 vaccines, but some may have lower antibody levels, especially those receiving glucocorticoids and B-cell depletion therapy. Further studies are needed to confirm these preliminary findings.
ANNALS OF INTERNAL MEDICINE
(2021)
Letter
Oncology
Oliver Van Oekelen et al.
Article
Immunology
Aaron J. Schmitz et al.
Summary: The emergence of SARS-CoV-2 antigenic variants poses a public health threat, but analysis of monoclonal antibodies suggests that some antibodies can neutralize various variants. The study also found that an antibody called 2C08 has neutralizing effects against multiple variants and can reduce viral load and morbidity in animal models.
Article
Immunology
Daniel Reynolds et al.
Summary: Severe cases of seasonal influenza or SARS-CoV-2 infection are associated with an influx of nonclassical monocytes, activated T cells, and plasmablast B cells into the lower airways, along with significantly elevated levels of 28 out of 35 measured cytokines. IP-10 concentration is the only cytokine that correlates between blood and bronchoalveolar lavage during severe infection.
JOURNAL OF IMMUNOLOGY
(2021)
Editorial Material
Public, Environmental & Occupational Health
Ying Liu et al.
Summary: The Delta variant is rapidly replacing other strains of SARS-CoV-2, with a higher R-0 value of 5.08 compared to the ancestral strain's 2.79. Increasing vaccine coverage and strengthening public health measures are now more urgent than ever to control the spread of the virus.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jackson S. Turner et al.
Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.
Article
Multidisciplinary Sciences
Jackson S. Turner et al.
Summary: SARS-CoV-2 mRNA vaccines induce a persistent germinal centre B cell response in humans, leading to the generation of robust humoral immunity, especially more significant in individuals previously infected with the virus.
Article
Multidisciplinary Sciences
Masaki Imai et al.
Summary: The P.1 variant of SARS-CoV-2 showed similar replicative abilities and pathogenicity in Syrian hamsters compared to early and contemporary strains. Sera/plasma from convalescent patients and BNT162b2 vaccinees had comparable neutralization titers against the P.1 variant, S-614D, and S-614G strains. Serum from a P.1-infected patient recognized the S-614D and S-614G strains less effectively than the P.1 variant.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Letter
Medicine, General & Internal
Matthew Frieman et al.
Article
Immunology
Stacey Schultz-Cherry et al.
Summary: The study found that receiving COVID-19 vaccination shortly after COVID-19-specific monoclonal antibody therapy can enhance and broaden antibody protection, questioning the necessity of delaying vaccination in this scenario.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Justin Xavier Moore et al.
Summary: In this sample, African Americans under the age of 30 and those experiencing housing insecurity due to the COVID-19 pandemic were more likely to be resistant to receiving a free COVID-19 vaccination.
Article
Pathology
Nikhil S. Sahajpal et al.
Summary: The laboratory underwent extensive testing and validation work to adapt to the rapidly evolving COVID-19 pandemic, making necessary adjustments and modifications to overcome challenges such as supply chain constraints.
ACADEMIC PATHOLOGY
(2021)
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Multidisciplinary Sciences
Abishek Chandrashekar et al.
Article
Multidisciplinary Sciences
Jingyou Yu et al.
Article
Biochemistry & Molecular Biology
Fatima Amanat et al.
Article
Biochemistry & Molecular Biology
Quan-Xin Long et al.
Editorial Material
Multidisciplinary Sciences
Florian Krammer et al.
Article
Multidisciplinary Sciences
Wei Deng et al.
Article
Microbiology
Amin Addetia et al.
JOURNAL OF CLINICAL MICROBIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Arthur W. D. Edridge et al.
Correction
Multidisciplinary Sciences
Peng Zhou et al.
Article
Immunology
Nisreen M. A. Okba et al.
EMERGING INFECTIOUS DISEASES
(2020)
